Working… Menu

Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma (CSCRGBM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03632135
Recruitment Status : Recruiting
First Posted : August 15, 2018
Last Update Posted : June 18, 2020
Information provided by (Responsible Party):
Cordgenics, LLC

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 30, 2021
Estimated Study Completion Date : January 31, 2022
Publications of Results:
Tulika Ranjan, Candace M. Howard, Jagan Valluri, Alexander Yu, Khaled Aziz, David Jho, Terrence Julien, Jody Leonardo, Anthony Alberico, Antonio Cortese, Krista Denning, and Pier Paolo Claudio. Prospective Analysis of Cancer Stem Cell Drug Response Assay for Glioblastoma Patients. J Clin Oncol 36, 2018 (suppl; abstr 2057) - ASCO Annual Meeting, Chicago, June 1-5, 2018.
Candace M Howard, Anthony Alberico, Jagan Valluri, Michael Griswold, and Pier Paolo Claudio. Analysis of chemo-predictive assay for targeting cancer stem cells in 41 glioblastoma patients. Journal of Clinical Oncology 2017 35:15_suppl, e13544-e13544
Pier Paolo Claudio, Sarah E Mathis, Rounak Nande, Anthony Alberico, Walter Neto, Logan Lawrence, James Denvir, Gerrit A. Kimmey, Aneel A. Chowdhary, Maria R. B. Tria Tirona, Mark Jeffrey Mogul, Terrence D Julien, Rida S Mazagri, Gerald Oakley, Krista L Denning, Thomas Dougherty, Linda Brown, and Jagan Valluri. Novel chemosensitivity assay for targeting cancer stem-like cells in brain tumors. Journal of Clinical Oncology 2014 32:15_suppl, e13012-e13012